2113.00 6.30 (0.30%)
NSENov 27, 2020 03:31 PM
There are 5 reports from 5 analysts covering Gland Pharma Ltd. available on trendlyne.com.
|Summary||Date||Stock||Broker||Price at Reco.||Target||Price at reco|
Change since reco(%)
|2020-11-09||Gland Pharma Ltd. +||HDFC Securities||IPO Note|
Gland Pharma Ltd - IPO Note Issue Open: Nov 09 Nov 11, 2020 Price Band: Rs. 1490 1500 *Issue Size: 43,196,968 eq shares (Fresh Issue of 8,333,333 eq sh + Offer for sale of 34,863,635 eq sh) Issue Size: Rs. 6436.3 6479.5 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 255.79 (June 30, 2020) Bid size: - 10 equity shares and in multiples thereof 100% Book built Issue Capital Structure: Pre Issue Equity: Rs. 15.49 cr Post issue Equity: Rs. 16.33 cr Listing: BSE & NSE
|2020-11-09||Gland Pharma Ltd. +||ICICI Securities Limited||IPO Note|
ICICI Securities Limited
Established in Hyderabad in 1978, Gland Pharma is one of the largest and fastest growing injectable-focused B2B companies, with a global footprint across 60 countries, including the US, Europe, Canada, Australia, India and other markets. It is a niche player in sterile injectables, oncology and ophthalmic solutions with focus on first-to-file, 505(b)(2) filings and NCE- 1s. Along with its partners Gland has 267 ANDA filings (101 owned) in the US as of Q1FY21, of which 215 were approved. The company has seven manufacturing facilities in India, comprising four formulations facilities with...
|2020-11-09||Gland Pharma Ltd. +||Nirmal Bang||IPO Note|
Valuation and Recommendation: Between FY18-20, Gland Pharma's revenues have grown at CAGR of 28% while Q1FY21's revenue grew by 31%. The company is engaged in complex products hence it has healthy profitability. Due to no debt and high cash, the company has strong PAT margins at 29.4% in FY20 which has improved from 19.8% in FY18. We believe the company is able to maintain CAGR of 25% for medium term with strong profitability. Though, Q1FY21 margins looks on the higher side, we believe EBITDA margins in the range of 35-38% are sustainable. The company intends to do capex with the IPO and cash on books, which can temporarily affect the return rations in near term however the long-term trajectory remains positive The issue price commands P/E of 31.7x FY20 and 19.5x Q1FY21 annualized earnings at the upper price of band of Rs 1490-1500, which is at upper end of Industry. However, going forward the higher revenue growth, improving profitability would make it a better choice among peers. We recommend Subscribe on the issue for long term gains.
|2020-11-09||Gland Pharma Ltd. +||Ashika Research||IPO Note|
The Company will not receive any proceeds of the Offer for Sale by the Selling Shareholder. (up to 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd, up to 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Ltd, up to 3,573,014 equity shares by Empower Discretionary Trust and up to 1,874,500...
|2020-11-08||Gland Pharma Ltd. +||Ventura||IPO Note|